TMO Thermo Fisher Scientific Inc. - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
TMO Stock | Fundamental Analysis & Investment Insights
NYSE
Healthcare
Diagnostics & Research
Current Price
Live
$618.72
Analyst Target
$651.52
+5.3%
Upside
52W High
$629.87
52W Low
$385.46
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
72%
Analysis Accuracy
Thermo Fisher Scientific's Piotroski F-Score of 5/9 indicates stable financial health, but the absence of an Altman Z-Score limits distress risk assessment. The stock trades at a significant premium to its Graham Number ($229.91) and intrinsic value estimate ($134.08), justified by solid profitability and consistent earnings beats, though recent insider selling and slowing growth raise caution. While analyst consensus is 'buy' with a target above current price, weak technical trend and decelerating YoY earnings growth suggest limited near-term upside. The company maintains strong margins and a manageable debt/equity ratio, but elevated valuation multiples relative to peers and minimal dividend strength constrain appeal.
Key Strengths
Consistent earnings beat record with 3 out of last 4 quarters exceeding estimates and a strong average surprise of 2.94%
High profitability metrics: 15.02% net margin, 19.28% operating margin, and 41.39% gross margin exceed sector averages
Solid balance sheet with a 1.50 current ratio and moderate 0.70 debt/equity ratio
Strong ROE of 13.12% despite industry headwinds, outperforming sector average ROE of 25.54% on a more conservative capital structure than peers like AMGN
Robust free cash flow generation implied by consistent earnings and low payout ratio, supporting reinvestment and shareholder returns
Key Risks
Valuation appears stretched with P/E of 35.76 significantly above sector average of 249.85 (distorted by outliers) and forward P/E of 25.10 still high
Recent insider activity is bearish: $88.23M in officer sales over the last 6 months with zero buys, suggesting lack of confidence at current levels
Earnings growth is decelerating: YoY EPS growth of 9.7% down from prior highs and Q/Q earnings growth recently negative at -0.90%
Technical trend score of 10/100 indicates strong bearish momentum despite short-term price recovery
Dividend strength is weak at 25/100 with a minimal yield of 0.28%, limiting appeal for income investors
AI Fair Value Estimate
Based on comprehensive analysis
$229.91
-62.8% below current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare TMO against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning TMO from our newsroom.
Newest → oldest
No matching news yet.